


How to bridge the gap between academia and industry
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.

BrighTNess trial: no benefit from the addition of veliparib to neoadjuvant chemotherapy in TNBC
Long-term outcomes of the phase III study confirm that only the addition of carboplatin to paclitaxel impacts on pathological complete response and event-free survival

The right to be forgotten reduces financial toxicity in cancer survivors
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated

More than one in six cancer patients experience long-term effects of COVID-19
OnCOVID study reveals that respiratory symptoms, fatigue and cognitive/psychological dysfunction persist after acute Sars-CoV-2 infection, with an impact on survival and oncological outcomes after recovery

Connecting and engaging those who care about cancer
International oncology experts reunited as one oncology community to share the latest advances in the field at the ESMO annual meeting starting next week

A Virtual Train to ESMO travelling through 15 countries
With the “departure” of the virtual ESMO train in August, the ESMO Young Oncologists Committee (YOC) and the ESMO Climate Change Task Force are creating new opportunities for networking and sharing knowledge, while raising awareness on how climate change hits on cancer care

One step back to move forward in oncology workforce
The scope of the oncology care across resource-diverse settings has been long debated.

Good night for good? Preventing sleeping cancer cells from awakening
Metastases are the main cause of cancer-related deaths. Preventing hibernating cancer cells from awakening therefore represents an urgent, unmet medical need.